Author details

Full Name

Lisa Zhang

Affiliation

National Institute of Child Health and Development

ORCID

Career Start Year

2010

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
35961004	Molecular mechanism underlying impaired hepatic autophagy in glycogen storage disease type Ib.	Hum Mol Genet	2023
35961004	Molecular mechanism underlying impaired hepatic autophagy in glycogen storage disease type Ib.	Hum Mol Genet	2023
37675898	Combination <i>BRAF<sup>V600E</sup></i> Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in <i>BRAF<sup>V600E</sup></i>-Mutant Anaplastic Thyroid Cancer.	Thyroid	2023
37675898	Combination <i>BRAF<sup>V600E</sup></i> Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in <i>BRAF<sup>V600E</sup></i>-Mutant Anaplastic Thyroid Cancer.	Thyroid	2023
33359667	Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing.	Mol Ther	2021
33359667	Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing.	Mol Ther	2021
32430177	Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia.	Biochem Biophys Res Commun	2020
32430177	Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia.	Biochem Biophys Res Commun	2020
31961433	The signaling pathways implicated in impairment of hepatic autophagy in glycogen storage disease type Ia.	Hum Mol Genet	2020
31937621	A Combinatorial Strategy for Targeting <i>BRAF</i> <sup>V600E</sup>-Mutant Cancers with BRAF<sup>V600E</sup> Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).	Clin Cancer Res	2020
31937621	A Combinatorial Strategy for Targeting <i>BRAF</i> <sup>V600E</sup>-Mutant Cancers with BRAF<sup>V600E</sup> Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).	Clin Cancer Res	2020
31961433	The signaling pathways implicated in impairment of hepatic autophagy in glycogen storage disease type Ia.	Hum Mol Genet	2020
30398411	Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.	Thyroid	2019
30398411	Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.	Thyroid	2019
30714174	An evolutionary approach to optimizing glucose-6-phosphatase-Î± enzymatic activity for gene therapy of glycogen storage disease type Ia.	J Inherit Metab Dis	2019
30714174	An evolutionary approach to optimizing glucose-6-phosphatase-Î± enzymatic activity for gene therapy of glycogen storage disease type Ia.	J Inherit Metab Dis	2019
30301885	Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors.	Nat Commun	2018
30301885	Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors.	Nat Commun	2018
30250647	Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response.	Oncotarget	2018
30250647	Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response.	Oncotarget	2018
28600475	Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.	Clin Cancer Res	2017
28600475	Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.	Clin Cancer Res	2017
28450405	Unique and Novel Urinary Metabolomic Features in Malignant versus Benign Adrenal Neoplasms.	Clin Cancer Res	2017
28334808	Downregulation of pathways implicated in liver inflammation and tumorigenesis of glycogen storage disease type Ia mice receiving gene therapy.	Hum Mol Genet	2017
28114280	RARRES2 functions as a tumor suppressor by promoting Î²-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.	Oncogene	2017
28114280	RARRES2 functions as a tumor suppressor by promoting Î²-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.	Oncogene	2017
28334808	Downregulation of pathways implicated in liver inflammation and tumorigenesis of glycogen storage disease type Ia mice receiving gene therapy.	Hum Mol Genet	2017
28450405	Unique and Novel Urinary Metabolomic Features in Malignant versus Benign Adrenal Neoplasms.	Clin Cancer Res	2017
27029493	Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers.	Clin Cancer Res	2016
26934320	Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer.	Oncotarget	2016
27296552	LOX is a novel mitotic spindle-associated protein essential for mitosis.	Oncotarget	2016
26873959	Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.	Clin Cancer Res	2016
27029493	Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers.	Clin Cancer Res	2016
27296552	LOX is a novel mitotic spindle-associated protein essential for mitosis.	Oncotarget	2016
26934320	Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer.	Oncotarget	2016
26873959	Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.	Clin Cancer Res	2016
25576159	Testosterone regulates thyroid cancer progression by modifying tumor suppressor genes and tumor immunity.	Carcinogenesis	2015
25576159	Testosterone regulates thyroid cancer progression by modifying tumor suppressor genes and tumor immunity.	Carcinogenesis	2015
25488748	miR30a inhibits LOX expression and anaplastic thyroid cancer progression.	Cancer Res	2015
25945839	Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.	Oncotarget	2015
25944801	Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer.	Clin Cancer Res	2015
25940539	Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.	Oncotarget	2015
25972243	Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.	Endocr Relat Cancer	2015
26222560	Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer.	N Engl J Med	2015
26244545	miR-126-3p Inhibits Thyroid Cancer Cell Growth and Metastasis, and Is Associated with Aggressive Thyroid Cancer.	PLoS One	2015
26446994	Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples.	Nucleic Acids Res	2015
26244545	miR-126-3p Inhibits Thyroid Cancer Cell Growth and Metastasis, and Is Associated with Aggressive Thyroid Cancer.	PLoS One	2015
26446994	Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples.	Nucleic Acids Res	2015
26222560	Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer.	N Engl J Med	2015
25972243	Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.	Endocr Relat Cancer	2015

1 - 50 of 106

Yunyun Zhou

Children's Hospital of Philadelphia

Career Start Year 2015

Number of shared co-authors 0

Jack Zhu

Center for Cancer Research, National Cancer Institute Bethesda

Career Start Year 2010

Number of shared co-authors 9

Cristina Ivan

The University of Texas MD Anderson Cancer Center

Career Start Year 2010

Number of shared co-authors 1

Alan L Ho

Memorial Sloan Kettering Cancer Center

Career Start Year 2009

Number of shared co-authors 0

Katayoon Kasaian

Ontario Institute for Cancer Research

Career Start Year 2008

Number of shared co-authors 3

Hui Xue

Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences

Career Start Year 2005

Number of shared co-authors 0

Aik Choon Tan

Huntsman Cancer Institute, The University of Utah

Career Start Year 2003

Number of shared co-authors 2

Xiaohu Zhang

National Center for Advancing Translational Sciences

Career Start Year 2003

Number of shared co-authors 2

Lixia Diao

The University of Texas MD Anderson Cancer Center

Career Start Year 2003

Number of shared co-authors 0

Yuelin J Zhu

National Cancer Institute, National Institutes of Health

Career Start Year 2002

Number of shared co-authors 20

Sandya Liyanarachchi

The Ohio State University Comprehensive Cancer Center, Comprehensive Cancer Center

Career Start Year 2002

Number of shared co-authors 2

Sooryanarayana Varambally

University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center

Career Start Year 2001

Number of shared co-authors 0

Fan Yang

West China Second Hospital, Sichuan University

Career Start Year 2000

Number of shared co-authors 2

Kristiina Iljin

VTT Technical Research Centre of Finland Ltd

Career Start Year 1999

Number of shared co-authors 1

Robert L Walker

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Career Start Year 1997

Number of shared co-authors 16

Jun Yao

The University of Texas MD Anderson Cancer Center

Career Start Year 1997

Number of shared co-authors 0

Lianbo Yu

The Ohio State University

Career Start Year 1997

Number of shared co-authors 0

Sung Tae Kim

Busan Paik Hospital, Inje University

Career Start Year 1996

Number of shared co-authors 0

John D Gordan

Quantitative Biosciences Institute (QBI), University of California San Francisco

Career Start Year 1996

Number of shared co-authors 0

Woong-Yang Park

Samsung Genome Institute, Samsung Medical Center

Career Start Year 1995

Number of shared co-authors 0

Huiling He

The Ohio State University Comprehensive Cancer Center

Career Start Year 1995

Number of shared co-authors 1

Tatsuhiro Shibata

Kurume University School of Medicine

Career Start Year 1993

Number of shared co-authors 6

Matthew D Ringel

The Ohio State University College of Medicine and Comprehensive Cancer Center

Career Start Year 1991

Number of shared co-authors 2

Thomas J Giordano

University of Michigan ann arbor

Career Start Year 1989

Number of shared co-authors 7

Wei Zhang

The University of Texas MD Anderson Cancer Center

Career Start Year 1988

Number of shared co-authors 0

Patrick Kwok-Shing Ng

The University of Texas MD Anderson Cancer Center

Career Start Year 1987

Number of shared co-authors 0

William C Hahn

Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute

Career Start Year 1987

Number of shared co-authors 0

Cuong Hoang-Vu

Center for Cancer Research, National Cancer Institute

Career Start Year 1985

Number of shared co-authors 5

Francisca Vazquez

Broad Institute of MIT and Harvard

Career Start Year 1979

Number of shared co-authors 0

Gordon B Mills

Knight Cancer Institute, Oregon Health and Sciences University

Career Start Year 1976

Number of shared co-authors 1

row(s) 1 - 30 of 30

Electron Kebebew

Stanford University School of Medicine

Co-authored papers 47

Naris Nilubol

Center for Cancer Research

Co-authored papers 21

Myriem Boufraqech

The University of Texas at Austin

Co-authored papers 20

Mei He

Sichuan University

Co-authored papers 13

Dhaval Patel

National Cancer Institute, National Institutes of Health

Co-authored papers 12

Sudheer Kumar Gara

National Cancer Institute, National Institutes of Health

Co-authored papers 10

Meenu Jain

Georgia Cancer Center, Augusta University

Co-authored papers 10

Min Shen

National Center for Advancing Translational Sciences, National Institutes of Health

Co-authored papers 10

Martha Quezado

National Cancer Institute (NCI), National Institutes of Health (NIH)

Co-authored papers 7

Yaqin Zhang

Jiangsu University Zhenjiang 212013

Co-authored papers 6

Maria J Merino

National Cancer Institute, National Institutes of Health

Co-authored papers 6

Amit Mehta

Center for Cancer Research, Maryland. Geisel School of Medicine at Dartmouth

Co-authored papers 5

Kelli Gaskins

Frederick National Laboratory for Cancer Research, National Institutes of Health

Co-authored papers 5

Susan R Davis

Co-authored papers 5

Sean Davis

Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington

Co-authored papers 5

Yi Liu-Chittenden

Department of Biochemistry and Howard Hughes Medical Institute, Stanford University

Co-authored papers 4

Paul S Meltzer

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Co-authored papers 4

Yonghong Wang

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Co-authored papers 4

Shweta Kotian

Center for Drug Evaluation and Research